These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9585861)

  • 1. Chronotherapeutics for cardiovascular disease.
    Anwar YA; White WB
    Drugs; 1998 May; 55(5):631-43. PubMed ID: 9585861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events.
    Carter BL
    Am J Health Syst Pharm; 1998 Nov; 55 Suppl 3():S17-23. PubMed ID: 9825045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease.
    Smolensky MH; Portaluppi F
    Am Heart J; 1999 Apr; 137(4 Pt 2):S14-S24. PubMed ID: 10097242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian variations and chronotherapeutic implications for cardiovascular management: a focus on COER verapamil.
    Glasser SP
    Heart Dis; 1999; 1(4):226-32. PubMed ID: 11720629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chronobiologic approach to the pharmacotherapy of hypertension and angina.
    Munger MA; Kenney JK
    Ann Pharmacother; 2000 Nov; 34(11):1313-9. PubMed ID: 11098347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
    Hermida RC
    Chronobiol Int; 2007; 24(4):749-75. PubMed ID: 17701685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronotherapeutics: are there meaningful differences among antihypertensive drugs?
    Poirier L; Lefebvre J; Lacourciere Y
    Curr Hypertens Rep; 1999 Aug; 1(4):320-7. PubMed ID: 10981084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities.
    Neutel JM; Smith DH
    Curr Opin Nephrol Hypertens; 1997 May; 6(3):250-6. PubMed ID: 9263668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure monitoring: dippers compared with non-dippers.
    White WB
    Blood Press Monit; 2000; 5 Suppl 1():S17-23. PubMed ID: 10904238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension.
    Weber MA; Fodera SM
    Rev Cardiovasc Med; 2004; 5(3):148-55. PubMed ID: 15346098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of COER-verapamil on circadian pattern of forearm vascular resistance and blood pressure.
    Nguyen BN; Parker RB; Noujedehi M; Sullivan JM; Johnson JA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1480-7. PubMed ID: 11185670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing treatment to the rhythm of disease. A short course in chronotherapeutics.
    Elliott WJ
    Postgrad Med; 2001 Aug; 110(2):119-22, 125-6, 129. PubMed ID: 11787411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronobiology and chronotherapeutics. Applications to cardiovascular medicine.
    Smolensky MH
    Am J Hypertens; 1996 Apr; 9(4 Pt 3):11S-21S. PubMed ID: 8722412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biorhythms and chronotherapy in cardiovascular disease.
    Cooke HM; Lynch A
    Am J Hosp Pharm; 1994 Oct; 51(20):2569-80. PubMed ID: 7847420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project.
    Hermida RC
    Chronobiol Int; 2016; 33(7):906-36. PubMed ID: 27221952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.
    White WB; Elliott WJ; Johnson MF; Black HR
    J Hum Hypertens; 2001 Feb; 15(2):135-41. PubMed ID: 11317194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronopharmacology and its impact on antihypertensive treatment.
    Lemmer B
    Acta Physiol Pharmacol Bulg; 1999; 24(3):71-80. PubMed ID: 10736610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study.
    Portaluppi F; Smolensky MH
    Chronobiol Int; 2010 Sep; 27(8):1652-67. PubMed ID: 20854140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.